Literature DB >> 9142127

Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells.

J Gong1, D Chen, M Kashiwaba, D Kufe.   

Abstract

Dendritic cells (DCs) are potent antigen-presenting cells that prime naive cytotoxic T-cells (CTLs). In this study, we have fused DCs with MC38 carcinoma cells. The fusion cells were positive for major histocompatibility (MHC) class I and II, costimulating molecules and intercellular cell adhesion molecule-1 (ICAM-1). The results show that the fusion cells stimulate naive T cells in the primary mixed lymphocyte reaction (MLR) and induce MC38 tumor-specific CTLs in vivo. Antibody-mediated depletion experiments demonstrate that induction of CD4+ and CD8+ CTLs protects against challenge with tumor cells. We also show that immunization with the fusion cells induces rejection of established metastases. These findings represent the first demonstration that fusions of DCs and tumor cells can be used in the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9142127     DOI: 10.1038/nm0597-558

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  106 in total

1.  Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo.

Authors:  Jin-Kun Zhang; Jun Li; Juan Zhang; Hai-Bin Chen; Su-Biao Chen
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

2.  In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids.

Authors:  R V Goddard; A G Prentice; J A Copplestone; E R Kaminski
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

Review 3.  A sense of tumour for the immune system.

Authors:  Stephen Todryk
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

4.  Lenalidomide enhances anti-myeloma cellular immunity.

Authors:  Katarina Luptakova; Jacalyn Rosenblatt; Brett Glotzbecker; Heidi Mills; Dina Stroopinsky; Turner Kufe; Baldev Vasir; Jon Arnason; Dimitri Tzachanis; Jeffrey I Zwicker; Robin M Joyce; James D Levine; Kenneth C Anderson; Donald Kufe; David Avigan
Journal:  Cancer Immunol Immunother       Date:  2012-06-24       Impact factor: 6.968

5.  Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer.

Authors:  Li-Zhi Niu; Jia-Liang Li; Jian-Ying Zeng; Feng Mu; Meng-Tian Liao; Fei Yao; Li Li; Chun-Yan Liu; Ji-Bing Chen; Jian-Sheng Zuo; Ke-Cheng Xu
Journal:  World J Gastroenterol       Date:  2013-06-14       Impact factor: 5.742

6.  Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro.

Authors:  D J Dunnion; A L Cywinski; V C Tucker; A K Murray; A B Rickinson; P Coulie; M J Browning
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

7.  Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo.

Authors:  Suzanne N Franki; Kristopher K Steward; David J Betting; Kamran Kafi; Reiko E Yamada; John M Timmerman
Journal:  Blood       Date:  2007-11-09       Impact factor: 22.113

Review 8.  The emerging role of immunotherapy in colorectal cancer.

Authors:  David Lynch; Adrian Murphy
Journal:  Ann Transl Med       Date:  2016-08

9.  Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.

Authors:  Maria R Parkhurst; Cormac DePan; John P Riley; Steven A Rosenberg; Suyu Shu
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

Review 10.  Novel immunotherapies.

Authors:  Qing Yi
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.